Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - ophthalmologicals - Луцентис prikazan kod odraslih za liječenje неоваскулярной (vlažna) senilne makularne degeneracije (amd)liječenje vida zbog хориоидальной неоваскуляризации (ХНВ)poremećaje vida zbog dijabetes pomagala макулярного edema (ДМО)poremećaje vida zbog макулярного edema sekundarne okluzije ретинальных vena (branch ili središnji glr glr).

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - metabolizam aminokiselina, urođene pogreške - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Κροατία - Κροατικά - HALMED (Agencija za lijekove i medicinske proizvode)

abbvie d.o.o., strojarska cesta 20, zagreb, hrvatska - neurotoksin clostridium botulinum tip a (900 kda) - prašak za otopinu za injekciju - 4 allergan jedinice/0,1 ml - urbroj: 1 bočica s praškom za otopinu za injekciju sadrži 50 ili 100 allergan jedinica neurotoksina tipa a (iz bakterije clostridium botulinum) nakon rekonstitucije otopina za injekciju sadržava 4 allergan jedinice u 0,1 ml

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

novartis europharm limited  - brolucizumab - mokro makularna degeneracija - ophthalmologicals - beovu prikazan kod odraslih za liječenje неоваскулярной (vlažna) senilne makularne degeneracije (amd).

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - ophthalmologicals - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Μαυροβούνιο - Κροατικά - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"farmont m.p." d.o.o. za proizvodnju, promet i usluge, export-import danilovgrad - bolnička, aparaturna oprema

Κροατία - Κροατικά - HALMED (Agencija za lijekove i medicinske proizvode)

genericon pharma gesellschaft m.b.h., hafnerstraße 211, graz, austrija - olmesartanmedoksomil - filmom obložena tableta - 10 mg - urbroj: jedna tableta sadrži 10 mg olmesartan medoksomila

Κροατία - Κροατικά - HALMED (Agencija za lijekove i medicinske proizvode)

genericon pharma gesellschaft m.b.h., hafnerstraße 211, graz, austrija - olmesartanmedoksomil - filmom obložena tableta - 20 mg - urbroj: jedna tableta sadrži 20 mg olmesartan medoksomila

Κροατία - Κροατικά - HALMED (Agencija za lijekove i medicinske proizvode)

genericon pharma gesellschaft m.b.h., hafnerstraße 211, graz, austrija - olmesartanmedoksomil - filmom obložena tableta - 40 mg - urbroj: jedna tableta sadrži 40 mg olmesartan medoksomila